Endo is a diversified specialty pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these essential medicines. Together, we are committed to helping everyone we serve live their best life. Learn more at www.endo.com or connect with us on LinkedIn.
Company profile
Ticker
NDOI
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
301390281
Latest filings (excl ownership)
8-K
1 Endo Investor Presentation September 2024
11 Sep 24
424B3
Prospectus supplement
29 Aug 24
10-Q
2024 Q2
Quarterly report
29 Aug 24
424B3
Prospectus supplement
27 Aug 24
8-K
Endo Announces Ceo Transition
27 Aug 24
8-K
Endo Reports Second-quarter 2024 Financial Results
27 Aug 24
EFFECT
Notice of effectiveness
1 Aug 24
S-8
Registration of securities for employees
31 Jul 24
424B3
Prospectus supplement
31 Jul 24
S-1/A
IPO registration (amended)
26 Jul 24
Latest ownership filings
No filings
Financial summary
Quarter (USD) | Jun 24 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | |||
---|---|---|---|---|---|---|
Cash on hand (at last report) | 460.39 mm | |||||
Cash burn (monthly) | 70.92 mm | |||||
Cash used (since last report) | 173.04 mm | |||||
Cash remaining | 287.34 mm | |||||
Runway (months of cash) | 4.1 |
Press releases
ENDO ANNOUNCES CEO TRANSITION
27 Aug 24
ENDO REPORTS SECOND-QUARTER 2024 FINANCIAL RESULTS
27 Aug 24
Endo Presents New Data at the American Podiatric Medical Association Annual Meeting
8 Aug 24
Endo to Host Investor Call on Second Quarter 2024 Financial Results
7 Aug 24
Endo to Host Investor Call on Second Quarter 2024 Financial Results
7 Aug 24